BRUCHA WEISBERGER has always been outfront fighting to save lives across COVID fake non-pandemic & mRNA vaccine & highlighted a substact I had written about Remdesivir & how NIH (Fauci) fraudulently

changed 'hard' patient-important PRIMARY outcomes in PROTOCOL e.g. death (as the drug failed the trial) to a non-patient outcome 'time to recovery' to declare benefit, disregarding DEVASTATING finding

Hat tip to Brucha:

Remdesivir and Paxlovid: Two dangerous and ineffective “covid treatments” which are shockingly STILL being used - and which you should absolutely REFUSE: Part 1

Money makers for the manufacturers, very harmful to patients

see protocol change next by Fauci and NIH and Francis Collins (scratching out the primary outcome as they were seeing the trial failing so chose a soft secondary outcome and made it the primary, seeking ANY outcome that showed any semblance of benefit yet this was UNIMPORTANT and they knew it, they knew they were being fraudulent here yet FDA let them get away with it and Remdesivir has turned out to be the harmful drug we knew it was, killing many, kidney and liver toxic…

what they did here below is academic fraud and not tolerated and done…you can change a protocol and be open, clear, transparent and explicit but you MUST never change a study protocol as Fauci did here by fishing and selecting an outcome showing something that is not important but making it the primary outcome and declaring ‘BENEFIT’…what was done here is FRAUD…and FDA still approved this Remdesivir on EUA.

this protocol change is not open to the public but I secured it and show you here (thank you Brucha, support her work)…these criminals…so that they could declare Remdesivir as the ‘standard of care’…they pretended that same day, that Wang et al. in LANCET which had shown Remdesivir to FAIL and was more deadly and stopped the study for harms…did not even exist…but we show it here…

Remdesivir and Paxlovid: Two dangerous and ineffective “covid treatments” which are shockingly STILL being used - and which you should absolutely REFUSE: Part 1

Start here:

'‘BS”D

When the drug companies can buy whatever media coverage they desire, and when the FDA is their best friend, there’s no limit to the promotion of dangerous and ineffective medications. Products which never should have seen the light of day have been used on hundreds of millions. Despite the carnage they’ve left in their wake, these poisons are, oddly, still being prescribed.

Nowadays, a patient has no choice but to become their own researcher and advocate, as the system is bought out and corrupted - but sadly, most patients have no idea that these “treatments” are not good for them. It is tragic how the unsuspecting elderly are often automatically given Remdesivir in the hospital. Remdesivir is frequently deadly, and even those who survive can be left with kidney damage. It is of no benefit and should never, ever be used. Remdesivir increases the risk of kidney failure 20-fold.

There are multiple lawsuits that have been filed for wrongful death due to organ failure brought on by Remdesivir. See the stories here: https://www.lezdotechmed.com/blog/remdesivir-lawsuits/

Paxlovid isn’t as dangerous as Remdesivir, but it has a black box warning. One of its components is a harmful HIV drug. Paxlovid has harmful interactions with many common medications, and can cause covid rebound, in which people get better briefly, and then get much sicker. Its efficacy is very poor compared to ivermectin.

I’ve written previously about both of these drugs, but I see it’s time to cover them again - as unsuspecting victims are still being poisoned. We’ve got to try to wake up the world.

Please see the information below so that you can help your loved ones make safer choices.

Part 1: Remdesivir

The results of the Remdesivir trials, and of the real-world use of this drug over the last almost-four years, prove that this “antiviral” is no more than a deadly sham.

Remdesivir in Trials

1. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics | NEJM shows more deaths (53.1%) in the Remdesivir treatment group than in any other. See Table 2:

https://www.nejm.org/doi/full/10.1056/NEJMoa1910993

2. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial | Lancet

In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.

Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

Dr. Paul Alexander gives more context about the Lancet study above:

This trial was stopped early because of no clinical benefit, & adverse events.

The LANCET Wang et al. publication (May 2020) came out the morning that the Fauci-NIH rolled out the fraudulent (NEJM) study.

The Lancet study was hidden & covered up by media, CDC, NIH, & FDA.

HERE is the fraudulent study by the NIH/Fauci’s NIAID used to gain approval for Remdesivir:

3. Remdesivir for the Treatment of Covid-19 — Final Report | NEJM

Before anything else, please take a look at who funded the trial (remember, the manufacturer of Remdesivir is Gilead.)

https://www.nejm.org/doi/full/10.1056/nejmoa2007764 https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19

Funding and Disclosures

The trial was sponsored and primarily funded by the NIAID, National Institutes of Health (NIH), Bethesda, MD.

Dr. Chu reports receiving consulting fees from Merck and GlaxoSmithKline, grant support from Sanofi Pasteur, and research supplies from Cepheid, Ellume, and Genentech; Dr. Luetkemeyer, receiving grant support, paid to the University of California, San Francisco, from Gilead; Dr. Paredes, receiving grant support and advisory fees from Gilead Sciences, Merck Sharp and Dohme, and ViiV Healthcare; Dr. Touloumi, receiving grant support from Gilead Sciences Europe; Dr. Benfield, receiving grant support from Pfizer, Novo Nordisk Foundation, Simonsen Foundation, and Lundbeck Foundation, grant support and advisory board fees from GlaxoSmithKline, grant support and lecture fees from Pfizer, teaching fees from Boehringer Ingelheim, grant support and teaching fees from Gilead, and teaching fees and advisory board fees from Merck Sharp and Dohme; Dr. Fätkenheuer, receiving grant support, advisory board fees, and travel support from Gilead Sciences and Janssen and grant support and advisory board fees from Merck Sharp and Dohme and ViiV Healthcare; Dr. Kortepeter, receiving consulting fees and serving on a board for Integrum Scientific; Dr. Pett, receiving grant support from Gilead Sciences and ViiV Healthcare; and Dr. Osinusi, being employed by Gilead Sciences. No other potential conflict of interest relevant to this article was reported.

Dr. Alexander explains the fraudulent trial used to get Remdesivir approved:

They engaged in methodological malfeasance by changing primary end-point to the protocol, because they were getting no benefit in mortality etc., the patient important outcomes. They also had the Wang et al. LANCET study out that morning showing remdesivir failed and was very, very harmful. They also had the failed Ebola trial with massive harms, deaths due to remdesivir. So they changed the secondary outcome to the primary outcome, time to clinical recovery… no longer patient important outcomes such as death or hospitalization etc.

(Source: palexander.substack.com, June 11 2022, “Remdesivir Trial…”)

Remdesivir Postmarketing Study Concludes That it Causes a High Rate of Kidney Damage

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907730/

Our findings, based on postmarketing real-life data from >5000 COVID-19 patients, support that kidney disorders, almost exclusively AKI, represent a serious, early, and potentially fatal adverse drug reaction of remdesivir. These results are consistent with findings from another group.⁴

Dr. Pierre Kory explains:

Why Are Hospitals Spending So Much On Ineffective C-19 Treatments?

By Dr. Pierre Kory MD February 24, 2022 (excerpts)

Remdesivir claimed the top spot for hospital drug spending in 2021, with sales earning Gilead $4.2 billion in the first nine months alone. The problem is that, at best, the drug doesn’t work.

At worst, however, Remdesivir is harmful. A subsequent analysis of the agency’s safety database found it likely caused kidney failure, and when independent trials (those not sponsored by a pharmaceutical company) are analyzed alone, there is a clear statistical trend to harm.

How is it possible that an ineffective and potentially dangerous drug that is scarcely used throughout the world received more money from U.S. hospitals than any other drug?

The answer is because our drug approval system is broken. It’s skewed towards expensive, patented, often marginally beneficial or unknowingly dangerous treatments produced by our pharmaceutical industry to the detriment of well-known, safe, cheap, generic drugs – and ultimately patients.

Remdesivir was approved based on a single, small trial with questionable results.

… we have undoubtedly spent so much on Remdesivir because hospitals have a major financial incentive to administer it. The Centers for Medicare & Medicaid Services established a system that provides a 20% bonus to each hospital’s bill to encourage them to use Remdesivir and other EUA approved high cost, patented medications.

https://www.realclearmarkets.com/articles/2022/02/24/why_are_hospitals_spending_so_much_on_ineffective_c-19_treatments_818382.html

Part of a comment by Jerry W. on Dr. Alexander’s March 27, 2023 Remdesivir article:

This just brings back HORRIBLE memories for me and makes me....a grown man....cry. My best friend (who also was my Brother-In-Law and how I met my wife) was murdered by this stuff 1 1/5 years ago. As they strapped him to the bed with twisty ties so he wouldn't be pulling out the stupid breathing machine … they stuffed down his throat. I was there when he passed and I knew what was going on (I'm a vendor / consultant in the medical field) and I physically get sick to my stomach every time I see the word Remdesivir.

Here is a screenshot from the law firm’s website of just one of the many accounts of Remdesivir deaths, for which families are now suing:

https://www.lezdotechmed.com/blog/remdesivir-lawsuits/

More on Lawsuits filed for Remdesivir deaths

Two women are suing Kaiser Permanente and Redlands Community Hospital in California for giving remdesivir to their husbands without consent. Both men died from kidney and organ failure after being administered remdesivir.

“The day he was admitted on August 12 they started the remdesivir and on [August 17] is when they were done,” Christina Briones told CBS News. “Five doses. [On] the 17th his kidneys started to fail.”

In California, lawsuits have been filed on behalf of at least 14 families against medical providers for prescribing remdesivir without providing necessary information about it, leading to the patients’ deaths.

Another wrongful death suit was filed in Nevada, after a patient died of kidney failure and respiratory failure a week after being given remdesivir.

https://childrenshealthdefense.org/defender/lawsuits-remdesivir-covid-cola/

Dr. Paul Marik, a pulmonary and critical care specialist and founding member of the Front Line Covid-19 Critical Care Alliance, explained that during the pandemic the only drug he was allowed to prescribe was remdesivir and that remdesivir increases the risk of kidney failure 20-fold. 

https://expose-news.com/2023/03/15/remdesivir-killed-100000-americans/

More links on Remdesivir dangers:

https://rumble.com/v1zn96i-dr.-paul-marik-on-the-danger-of-remdesivir-at-senator-johnsons-covid-19-vac.html

https://twitter.com/SpartaJustice/status/1617615000977412096?t=A153weX8FGFS3sExtrzx9A&s=19

https://threadreaderapp.com/thread/1650126479227863043.html

https://www.redvoicemedia.com/video/2022/12/we-murdered-people-remdesivir-the-pseudomedicine-death-warrant-for-american-citizens/

JUST SAY NO!

Please see Part 2 for Paxlovid warning information.’